Scarica l'app Stockscreener
302.96
0.07%
0.22
Dopo l'orario di chiusura:
302.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Hogan Lovells Cadwalader advises Ligand on financing agreement with AvenCell Therapeutics - Legal Desire
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook? - Yahoo Finance
Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com - Investing.com Nigeria
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance
Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
LGND Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Barclays initiates Ligand Pharma stock with overweight rating By Investing.com - Investing.com South Africa
Barclays initiates Ligand Pharma stock with overweight rating - Investing.com
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Director Martine Zimmermann Reports RSU Tax Withholding on 115 Shares - Kalkine Media
Form 4 Ligand Pharmaceuticals Incorporated For: 24 September By Investing.com - Investing.com Canada
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies - TradingView
LGND Reiterated by HC Wainwright & Co. -- Price Target Maintained at $358 - GuruFocus
LGND Looks 60.8% Overvalued on GF Value™ - GuruFocus
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com - Investing.com Canada
LGND Looks 60.6% Overvalued on GF Value™ - GuruFocus
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - marketscreener.com
Up to $47 million could help advance AvenCell's treatments for two blood cancers. - Stock Titan
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
AvenCell Therapeutics, Inc. announced that it expects to receive $6 million in funding from Ligand Pharmaceuticals Incorporated - marketscreener.com
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte
LGND Maintained by Citigroup -- Price Target Raised to $397 - GuruFocus
Sydnexis sells Ryjunea EMEA royalty rights to Ligand for $23 million upfront - The Pharma Letter
Ligand Acquires Royalty Rights in Santen’s Ryjunea from Sydnexis for $23 Million - VisionMonday.com
LGND Looks 56.0% Overvalued on GF Value™ - GuruFocus
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - Yahoo Finance
A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. - Stock Titan
Ligand Acquires Ryjunea Royalty Rights From Sydnexis for $23 Million - Minichart
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - Yahoo Finance
Ligand Acquires Ryjunea EMEA Royalty Rights for $23M Upfront - TradingView
About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. - Stock Titan
LGNZZ 8-K FilingsLIGAND PHARMS BETA CVR SEC 8-K - Stock Titan
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million - GlobeNewswire
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
Ligand Pharmaceuticals seen as a strong midcap pharma despite recent 10% drop, with promising royalty assets. - Pluang
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Preset plan drives 5,000-share sale at Ligand Pharmaceuticals (LGND) - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):